Kite Presents Results of Yescarta (axicabtagene ciloleucel) in P-II ZUMA-5 Trial for R/R Follicular Lymphoma at EHA 2021
Shots:
- The P-II ZUMA-5 trial assessing Yescarta in 146 patients aged ≥18rs. with r/r iNHL include FL- prior treated with at least 2L of systemic therapy
- Results: 94% of patients achieved a response @18mos.- & 2EPs of mPFS and OS were not yet reached. In a weighted analysis- the results compared with ZUMA-5 patients vs SCHOLAR-5 patients- therapy showed superior OS & PFS over currently available treatments
- Patients achieved a response (94% vs 50%) @median follow-up of 26.2 mos.- reduction in risk of disease progression (58% vs 70%)- relapse or death vs current therapies in a control cohort- m-PFS & OS (12.7 & 59.8 mos.) in a control cohort- respectively
| Ref: Business Wire | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com